Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2025 08:30 ET | Source: Lantheus Holdings, Inc.

Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease

BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
September 30, 2025 12:10 ET | Source: National Down Syndrome Society

LuMind IDSC Foundation Merges into the National Down Syndrome Society to Advance Down Syndrome Research and Health Equity

Washington DC, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The National Down Syndrome Society (NDSS) announced that LuMind IDSC Foundation, the nation’s leading Down syndrome and Alzheimer’s disease research...
September 22, 2025 09:15 ET | Source: Longeveron

Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa

Longeveron hosting partnering discussions for its Alzheimer's disease stem cell therapy program at Cell & Gene Meeting on the Mesa.
September 15, 2025 08:30 ET | Source: Actinogen Medical

Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease

SYDNEY, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces the successful conduct of its scheduled Type C meeting (written response) on Alzheimer’s disease (AD) with...
September 12, 2025 07:20 ET | Source: Galimedix Therapeutics, Inc.

Progress in clinical development for Alzheimer’s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator

GAL-101 was well tolerated; excellent safety and pharmacokinetic profile strongly support oral administrationGAL-101 effectively crosses the blood-brain barrier, supporting further development in...
September 03, 2025 16:05 ET | Source: Longeveron

Longeveron® Announces Key Leadership Updates

Longeveron BOD appoints Interim CEO and Executive Chairman of BOD. Board plans to conduct a national search to identify a permanent CEO.
August 20, 2025 09:15 ET | Source: Longeveron

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Longeveron will present and host investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025.
August 13, 2025 16:05 ET | Source: Longeveron

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated...
August 13, 2025 06:00 ET | Source: Neuronascent, Inc.

Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions

BALTIMORE., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the Phase 1a trial in aged human subjects of its...
July 22, 2025 07:00 ET | Source: Lantheus Holdings, Inc.

Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), today announced the successful completion of its previously disclosed...